Steward Partners Investment Advisory LLC Buys 28,216 Shares of Kenvue Inc. (NYSE:KVUE)

Steward Partners Investment Advisory LLC raised its holdings in shares of Kenvue Inc. (NYSE:KVUE - Free Report) by 143.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 47,938 shares of the company's stock after buying an additional 28,216 shares during the period. Steward Partners Investment Advisory LLC's holdings in Kenvue were worth $1,023,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of KVUE. Alerus Financial NA increased its stake in shares of Kenvue by 0.3% during the third quarter. Alerus Financial NA now owns 191,345 shares of the company's stock valued at $4,426,000 after buying an additional 491 shares during the period. Kiley Juergens Wealth Management LLC increased its position in Kenvue by 1.9% during the 4th quarter. Kiley Juergens Wealth Management LLC now owns 27,110 shares of the company's stock valued at $579,000 after purchasing an additional 500 shares during the period. Principle Wealth Partners LLC raised its holdings in Kenvue by 3.7% in the 4th quarter. Principle Wealth Partners LLC now owns 14,194 shares of the company's stock worth $303,000 after purchasing an additional 500 shares in the last quarter. White Pine Capital LLC lifted its position in shares of Kenvue by 1.0% in the 4th quarter. White Pine Capital LLC now owns 54,572 shares of the company's stock worth $1,165,000 after purchasing an additional 542 shares during the period. Finally, Deseret Mutual Benefit Administrators lifted its position in shares of Kenvue by 29.0% in the 4th quarter. Deseret Mutual Benefit Administrators now owns 2,528 shares of the company's stock worth $54,000 after purchasing an additional 568 shares during the period. 97.64% of the stock is owned by institutional investors.

Remove Ads

Kenvue Stock Performance

Shares of NYSE KVUE traded down $0.38 during midday trading on Wednesday, hitting $23.12. 4,576,873 shares of the stock traded hands, compared to its average volume of 14,448,409. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 1.00. Kenvue Inc. has a one year low of $17.67 and a one year high of $24.46. The firm has a market capitalization of $44.18 billion, a P/E ratio of 43.65, a PEG ratio of 2.62 and a beta of 1.25. The firm has a 50-day moving average of $21.74 and a two-hundred day moving average of $22.36.

Kenvue (NYSE:KVUE - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The company reported $0.26 EPS for the quarter, meeting the consensus estimate of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. On average, equities analysts forecast that Kenvue Inc. will post 1.14 EPS for the current fiscal year.

Kenvue Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were given a dividend of $0.205 per share. The ex-dividend date of this dividend was Wednesday, February 12th. This represents a $0.82 annualized dividend and a dividend yield of 3.55%. Kenvue's payout ratio is 154.72%.

Analyst Upgrades and Downgrades

Several analysts have commented on the stock. Deutsche Bank Aktiengesellschaft lowered shares of Kenvue from a "buy" rating to a "hold" rating and lowered their price objective for the stock from $25.00 to $24.00 in a report on Thursday, December 12th. Citigroup dropped their price target on Kenvue from $25.00 to $21.00 and set a "neutral" rating on the stock in a research report on Wednesday, January 15th. UBS Group decreased their price objective on Kenvue from $23.00 to $21.00 and set a "neutral" rating for the company in a report on Friday, February 7th. Piper Sandler boosted their target price on shares of Kenvue from $24.00 to $27.00 and gave the company an "overweight" rating in a report on Monday, February 24th. Finally, Royal Bank of Canada reiterated a "sector perform" rating and issued a $24.00 price target on shares of Kenvue in a research note on Monday, February 3rd. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and five have given a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $23.75.

Kenvue Company Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.